CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc.

弗吉尼亚州夏洛茨维尔和印第安纳波利斯，2023年11月6日（GLOBE NEWSWIRE）-Acumen Pharmaceuticals，Inc。（纳斯达克股票代码：ABOS）（“Acumen”或“公司”），一家临床阶段生物制药公司开发一种靶向有毒可溶性淀粉样蛋白β寡聚体（aβO）治疗阿尔茨海默病（AD）的新型治疗剂，今天宣布与Halozyme Therapeutics Inc.达成全球非独家合作和许可协议。

(“Halozyme”). The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody. ENHANZE® has been commercially validated in seven approved therapies, with global collaborations covering more than 60 therapeutic targets.

（“Halozyme”）。该合作将为基于重组人透明质酸酶PH20酶（rHuPH20）的Halozyme的ENHANZE®药物递送技术提供敏锐的途径，用于开发ACU193的皮下制剂，ACU193是第一个临床阶段aβO靶向抗体。ENHANZE®已经在七种经过批准的疗法中进行了商业验证，全球合作涵盖了60多个治疗目标。

Acumen intends to explore using ENHANZE® with ACU193 and plans to initiate Phase 1 development in human subjects in mid-2024 to compare the pharmacokinetics (PK) of a subcutaneous form of ACU193 to the intravenous (IV) form. Acumen recently completed the Phase 1 INTERCEPT-AD trial in patients with early AD, which demonstrated robust, dose dependent target engagement for ACU193 and additionally produced amyloid plaque reduction following three administrations of ACU193 at 25 mg/kg or 60 mg/kg.

Acumen打算探索将ENHANZE®与ACU193一起使用，并计划于2024年中期启动人类受试者的1期开发，以比较皮下形式的ACU193与静脉内（IV）形式的药代动力学（PK）。Acumen最近完成了阶段1 INTERCEPT-AD试验在早期AD患者中表现出强大的，ACU193的剂量依赖性靶标参与，并且在以25mg/kg或60mg/kg三次施用ACU193后另外产生淀粉样斑块减少。

At or near a three-month timepoint, ACU193 reduced amyloid plaque to a comparable level as that observed with administration of LEQEMBI®. Under the terms of the agreement, in return for an upfront payment to Halozyme and other considerations, Acumen will receive non-exclusive rights to ENHANZE®. Acumen is obligated to make future payments to Halozyme, subject to achievement of specified development, regulatory and sales-based milestone.

在三个月的时间点或接近三个月的时间点，ACU193将淀粉样斑块减少至与施用LEQEMBI®观察到的水平相当的水平。根据协议条款，作为向Halozyme支付的预付款和其他考虑事项，Acumen将获得ENHANZE®的非排他性权利。Acumen有义务在实现特定的开发，监管和销售里程碑的前提下向Halozyme支付未来的款项。